Lifeward / ReWalk Robotics
About
About Lifeward / ReWalk Robotics
Lifeward, formerly ReWalk Robotics, develops powered mobility and rehabilitation systems for people with lower-limb disabilities. ReWalk personal exoskeletons support upright walking for eligible users, while clinical products provide repeated gait training under professional supervision.
The portfolio also includes rehabilitation technologies acquired with AlterG, extending care across neurological recovery, mobility training and anti-gravity exercise. Lifeward combines wearable hardware, sensing, control software, fitting and clinician education. Each product follows its own medical indication, regulatory clearance and reimbursement pathway, with service delivered through clinical and personal-use channels.
Products
- ReWalk 7 Personal Exoskeleton
ReWalk Personal Exoskeleton
Supply
Supply chain relationships
- Sanmina
Inbound - Manufacturing - Sanmina manufactures and sources components for Lifeward ReWalk and ReStore exoskeletons
Source - maxon
Inbound - actuation and motion control - The earlier ReWalk 6.0 configuration used maxon RE 40 motors and GP 42 C planetary gearheads
Source - Sanmina
Inbound - Manufacturing - In FY2023, Sanmina contract-manufactured ReWalk exoskeletons and ReStore exo-suits at Ma'alot, Israel
Source
Financials
- LFWD - NASDAQ - USD
Team
- Mark Grant - President and Chief Executive Officer - His role covers Lifeward's ReWalk exoskeleton, AlterG anti-gravity systems and rehabilitation technology portfolio.
Timeline
Events
- 2026-08-05 - Deployment - Lifeward and Ottobock Care open six-month ReWalk 7 access programme
Ottobock Care’s clinic network will support patient evaluation and staff training during the programme. The partners will coordinate reimbursement support alongside clinical access. The announcement describes a six-month national pilot rather than a permanent network-wide rollout.
Source - 2025-04-15 - Product Launch - Lifeward launches ReWalk 7 exoskeleton sales in the U.S.
Lifeward launched U.S. sales of the ReWalk 7 personal exoskeleton. The launch followed FDA clearance in March 2025. The product is used to support standing and walking for individuals with spinal cord injury.
Source - 2025-03-13 - Regulatory - Lifeward receives FDA clearance for ReWalk 7 exoskeleton
Lifeward received 510(k) FDA clearance for the ReWalk 7 personal exoskeleton. The seventh-generation ReWalk device is designed for individuals with spinal cord injury. The clearance followed prior FDA clearance for ReWalk stair and curb functionality and CMS national reimbursement policy development.
Source
Relations
Relationships
- Ottobock
Rewalk 7 Access Programme Partner - Lifeward and Ottobock Care launched a six-month ReWalk 7 access programme across more than 50 U.S. clinics.
- Ottobock Care
Exoskeleton Access Programme Partner - Lifeward and Ottobock launched a six-month ReWalk 7 access programme across more than 50 U.S. clinics.